Cost-effectiveness of Antihyperlipemic Therapy in the Prevention of Coronary Heart Disease: The Case of Cholestyramine

JAMA: The Journal of the American Medical Association

Volumn 258, Issue 17, 1987, Pages 2381-2387

  Oster, Gerry ^a   Epstein, Arnold M ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Family Foundation Faculty Scholar General Internal Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; COLESTYRAMINE;

ADULT; AGED; ECONOMIC ASPECT; EPIDEMIOLOGY; HEART; HUMAN; ISCHEMIC HEART DISEASE; PREVENTION; THERAPY;

ADULT; AGED; CHOLESTYRAMINE; CORONARY DISEASE; COST-BENEFIT ANALYSIS; HUMAN; HYPERCHOLESTEROLEMIA; LIFE EXPECTANCY; MALE; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T;

EID: 0023264964     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1987.03400170067025     Document Type: Article

References (23)

1. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in the incidence of coronary heart disease. JAMA 1984;251:351-364.
2. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-374.
3. Lowering blood cholesterol to prevent heart disease, CONSENSUS CONFERENCE. JAMA 1985; 253:2080-2086.
4. Kannel WB: The role of cholesterol in coronary atherogenesis: Symposium on atherosclerosis. Med Clin North Am 1974;58:363-379.
5. Stamler J: Population studies, in Levy RI, Rifkind B, Dennis B, et al.: (eds): Nutrition, Lipids, and Coronary Heart Disease. New York, Raven Press, 1979, pp 25-88.
6. Kannel WB: Prospects for risk factor modification to reduce the risk of reinfarction and premature death. J Cardiac Rehab 1981;1:63-71.
7. Weinstein MC, Stason WB: Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977;296:716-721.
8. Weinstein MC, Stason WB: Hypertension: A Policy Perspective. Cambridge, Mass, Harvard University Press, 1976.
9. Vital Statistics of the United States, 1980, volume 2, section 6: Life Tables, US Dept of Health and Human Services publication (PHS) 84-1104. National Center for Health Statistics, 1984.
10. Physicians’ Desk Reference, ed 40. Oradell, NJ, Medical Economics Books, 1986.
11. McGee DL: Section 28: Probability of developing certain cardiovascular diseases in eight years at specified values of some characteristics, in Kannel WB, Gordon T (eds): The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease, US Dept of Health, Education, and Welfare publication (NIH) 74-610. Bethesda, Md, Public Health Service, 1977.
12. Sorlie P: Section 32: Cardiovascular diseases and death following myocardial infarction and angina pectoris: Framingham Study, 20-year follow-up, in Kannel WB, Gordon T (eds): The Framingham Study: An Epidemiological Investigation of’ Cardiovascular Disease, US Dept of Health, Education, and Welfare publication (NIH) 77-1247. Bethesda, Md, Public Health Service, 1977.
13. Health, United States, 1983. US Dept of Health and Human Services publication (PHS) 84-1232. National Center for Health Statistics, 1983.
14. Goldman L, Cook EF: The decline in ischemic heart disease mortality rates: An analysis of the comparative effects of medical interventions and changes in lifestyle. Ann Intern Med 1984;101:826-836.
15. Oster G, Epstein AE: Primary prevention and coronary heart disease: The economic benefits of lowering serum cholesterol. Am J Public Health 1986;76:647-656.
16. Shurtleff D: Section 30: Some characteristics related to the incidence of cardiovascular disease and death: Framingham Study, 18-year follow-up, in Kannel WB, Gordon T (eds): The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. US Dept of Health, Education, and Welfare publication (NIH) 74-599. Bethesda, Md, Public Health Service, 1974.
17. Levit KR, Lazenby H, Waldo DR, et al.: National health expenditures, 1984. Health Care Fin Rev 1985;7:1-35.
18. Hodgson TA, Kopstein AN: Health care expenditures for major diseases in 1980. Health Care Fin Rev 1984;5:1-12.
19. Weinstein MC, Stason WB: Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annu Rev Public Health 1985;6:41-63.
20. The Lovastatin Study Group II: Therapeutic response to lovastatin (Mevinolin) in nonfamilial hypercholesterolemia: A multicenter study. JAMA 1987;256:2829-2834.
21. Himmelstein DU, Woolhandler S: Costs and effects: The lipid research trial and the Rand experiment. N Engl J Med 1985;311:1512-1513.
22. Berwick DM, Cretin S, Keeler E: Cholesterol, Children, and Heart Disease: An Analysis of Alternatives. New York, Oxford University Press Inc, 1980.
23. Taylor WC, Pass TM, Shepard DS, et al.: Cholesterol reduction and life expectancy: A model incorporating multiple risk factors. Ann Intern Med 1987;106:606-614.